By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that HRS-1780 tablets have received approval from China’s National Medical Products Administration (NMPA) to initiate Phase 2/3 clinical trials for the treatment of uncontrolled hypertension or resistant hypertension. The investigational agent is a mineralocorticoid receptor antagonist (MRA) designed to address significant unmet needs in patients who fail to achieve blood pressure control with standard therapies.
Development Overview
| Item | Detail |
|---|---|
| Sponsor | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) |
| Drug Class | Mineralocorticoid receptor antagonist (MRA) |
| Indication | Uncontrolled hypertension / Resistant hypertension |
| Trial Phase | Phase 2/3 |
| Regulatory Milestone | NMPA clinical trial approval |
| Approval Date | 28 Jul 2026 |
| Additional Indications | Chronic kidney disease, Primary aldosteronism (both Phase 2/3) |
Drug Profile & Clinical Rationale
- Molecule: HRS-1780
- Mechanism: Selective mineralocorticoid receptor antagonism
- Therapeutic Positioning: Preferred add-on therapy to standard care for resistant hypertension
- Market Gap: No similar MRA product currently marketed in China
- Global Precedent: Esaxerenone (selective non-steroidal MRA) approved and launched in Japan for hypertension
- Development Strategy: Multi-indication approach targeting related cardio-renal conditions
Clinical Context – Resistant Hypertension
| Parameter | Clinical Significance |
|---|---|
| Definition | Blood pressure ≥140/90 mmHg despite use of three antihypertensive agents including a diuretic |
| Prevalence | Affects approximately 10-20% of hypertensive patients globally |
| Current Standard | MRAs recommended as preferred fourth-line add-on therapy |
| Unmet Need | Limited MRA options available in China market |
| Treatment Goal | Achieve target blood pressure to reduce cardiovascular and renal complications |
MRAs have established efficacy in reducing blood pressure and providing cardio-renal protection in resistant hypertension, making them a cornerstone of guideline-recommended management strategies.
Market Impact & Strategic Implications
- China Hypertension Market: Addresses critical gap in China’s hypertension treatment landscape where an estimated 270 million adults suffer from high blood pressure
- First-Mover Advantage: Potential to become the first selective MRA specifically indicated for resistant hypertension in China
- Multi-Indication Portfolio: Concurrent development in chronic kidney disease and primary aldosteronism creates synergistic commercial opportunities across cardio-renal indications
- Competitive Differentiation: Builds on global validation of MRA class while addressing China-specific market needs
- Healthcare Economics: Effective resistant hypertension management could significantly reduce long-term cardiovascular event costs in China’s healthcare system
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for HRS-1780. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech